Role of Traditional Chinese Medicine in Bone Regeneration and Osteoporosis

Zhicai Peng, Ronghua Xu* and Qinjian You

Department of Orthopaedics, Yongchuan Hospital of Traditional Chinese Medicine, Chongqing Medical University, Chongqing, China

According to the World Health Organization (WHO), osteoporosis is a systemic bone disability marked by reduced bone mass and microarchitectural degeneration of osseous cells, which leads to increased bones feebleness and fractures vulnerability. It is a polygenetic, physiological bone deformity that frequently leads to osteoporotic fractures and raises the risk of fractures in minimal trauma. Additionally, the molecular changes that cause osteoporosis are linked to decreased fracture repair and delayed bone regeneration. Bones have the ability to regenerate as part of the healing mechanism after an accident or trauma, including musculoskeletal growth and ongoing remodeling throughout adulthood. The principal treatment approaches for bone loss illnesses, such as osteoporosis, are hormone replacement therapy (HRT) and bisphosphonates. In this review, we searched literature regarding the Traditional Chinese medicines (TCM) in osteoporosis and bone regeneration. The literature results are summarized in this review for osteoporosis and bone regeneration. Traditional Chinese medicines (TCM) have grown in popularity as a result of its success in curing ailments while causing minimal adverse effects. Natural Chinese medicine has already been utilized to cure various types of orthopedic illnesses, notably osteoporosis, bone fractures and rheumatism with great success. TCM is a discipline of conventional remedy that encompasses herbal medication, massage (tui na), acupuncture, food, and exercise (qigong) therapy. It is based on more than 2,500 years of Chinese healthcare profession. This article serves as a comprehensive review summarizing the osteoporosis, bone regeneration and the traditional Chinese medicines used since ancient times for the management of osteoporosis and bone regeneration.

Keywords: osteoporosis, bone regeneration, traditional Chinese medicines, decoction, adrenocorticotropic hormone (ACTH)
INTRODUCTION

According to WHO, by 2022, the number of persons living with osteoporosis in the America is projected to boost from around 10 million to over 14 million (Bartl and Frisch, 2004; Burge et al., 2007). Due to modern civilizations’ constantly expanding life expectancy, the global implications of osteoporosis and delayed bone repair are massive. As a result, the clinical need to reverse bone loss, promote bone development, and enhance osteogenesis is rising, and it is a critical problem for medical professionals (Russow et al., 2019). Hormonal and metabolic abnormalities are the most common etiologies of osteoporosis. Nevertheless, osteoimmunology has shown that the immune cells and immunological parameters perform key regulating roles in the progression of osteoporosis. The immune system’s aberrant stimulation disrupts the equilibrium between osteoclasts and osteoblasts, creating instability in bone remodeling and osteoporosis (Guerrini and Takayanagi, 2014; Limmer and Wirtz, 2017). Over 50 years of age, about one-third of women and one-fifth of men will develop at least one bone fracture due to osteoporosis (Sözen et al., 2017).

For the prophylaxis and therapy of osteoporosis, the Federal Drug Administration (FDA) of United States has authorized a number of medications that function by preventing bone resorption or reduce the incidence of fractures (anabolic agents). Bisphosphonates, competitive oestrogen receptor modulators, and the monoclonal antibody denosumab are examples of drugs that prevent bone degradation but do not induce bone regeneration (Russow et al., 2019). Abaloparatide and Teriparatide are the currently US Food and Drug Administration (FDA) approved anabolic agents for the treatment of osteoporosis in the United States approved in 2017 and 2002 respectively (Miller et al., 2016; Haas and LeBoff, 2018). The principal treatment approaches for bone loss illnesses, such as osteoporosis, are hormone replacement therapy (HRT) and bisphosphonates. Continuous HRT is associated to high risk of mammary cancer and endometrial, as well as coronary artery problems and other cardiac disorders whereas bisphosphonates are responsible for the osteonecrosis of the jaws and bones (Dinger et al., 2016; He et al., 2017; Spivakovsky, 2017). The clinical usage of HRT and bisphosphonates is limited due to these adverse effects. As a result, new treatment strategies are needed to produce osteoporosis treatments that are somewhat liable to cause fewer adverse reactions (Lungu et al., 2018). Cathepsin-K is a cysteine protease that is found in significant amounts in osteoclasts. Even though there are various additional cathepsins with large anatomical concentrations, any antagonists for clinical usage must have a higher selectivity if they are to be safe. Balicatib preceded through phase 2 clinical studies, however due to cutaneous and respiratory adverse effects, onward research was halted (Reid, 2008). Odanacatib concluded effectively phase 2 studies with no apparent potential risks. It decreases osteoclastogenesis indicators by around 70% and induces variations in spine bone concentrations that are similar in many aspects with active bisphosphonates if administered as a fortnightly oral route (Bone et al., 2007).

Traditional Chinese medicines (TCM) have grown in popularity as a result of its success in curing ailments while causing minimal adverse affects. Natural Chinese medicine has already been utilized to cure various types of orthopaedic illnesses, notably osteoporosis, bone fractures and rheumatism with great success (Mukwaya et al., 2014; Suvarna et al., 2018). The widespread use of TCM for musculoskeletal disorders has been existed for many years, both in rural as well as in urban regions. Topical herbal formulations are especially beneficial in cases of joint injuries, inflammations, but potentially in fractured bones (Jiang and Ye, 2005). According to latest research findings, these Chinese medicinal approaches for the management of osteoporosis emerge to have equally anticytabolic and anabolic impacts by boosting osteogenesis and minimizing extremely unbalanced bone turnover, resulting in improved bone mineral density as well as minimal bone microstructural degradation (Wang et al., 2017a; He et al., 2017).

This review focuses on and acknowledges the scientific proof for the possible usage of traditional Chinese medicine in the management of osteoporosis and bone regeneration.

OSTEOPOROSIS AND BONE REGENERATION

Osteoporosis is a skeletal disorder that is characterized by poor bone microarchitecture/mineralization, reduced bones’ mineral density (BMD), and/or diminished bone growth. This asymptomatic illness typically goes untreated till it emerges as minimal fractures of the spine, wrist, pelvis, proximal humerus, and/or hips, which commonly necessitates hospitalizations (Cosman et al., 2014; Jeremiah et al., 2015). There are two types of osteoporosis: primary and secondary. Primary osteoporosis: 1) postmenopausal affects mostly the vertebral column trabeculae and is common in women aged 45 to 65. It is caused by the oestrogen insufficiency and impairment of ovarian function. 2) senile in women over the age of 70–75, which is caused by a reduction in vitamin D and calcium consumption, decreased vitamin D generation and metabolism in the body, diminished intestinal absorption, and the ageing process: 3) Idiopathic (juvenile) fractures—a rare type that affects people of reproductive age (below 40). Disorders or medicines that damage bone cells cause secondary osteoporosis. Continuous utilization of selective serotonin receptor inhibitors, glucocorticoids, androgen deprivation therapy, proton pump inhibitors, thiazolidinedione, calcineurin inhibitors, heparin, and various chemotherapies, such as methotrexate, might cause osteoporosis (Ivanova et al., 2015).

Primary osteoporosis is frequently linked to advanced age and a lack of sex hormones. The ongoing degradation of the trabeculae in bone causes age-related osteoporosis. Furthermore, the decrease in oestrogen levels in older women leads to greater osteoporosis. Sex-hormone–binding globulin downregulates the male sex hormones as they mature, which might also result in bone loss over time (Jeremiah et al., 2015; Society, 2021). Multiple concomitant conditions and/or drugs can lead to secondary osteoporosis. The imbalance of vitamin D,
calcium, and sex hormones is frequently linked in disorders associated with osteoporosis. Men on androgen-deprivation therapy (ADT) for prostate cancer, for example, have a higher likelihood of osteoporosis (Shahinian et al., 2005; Schnatz et al., 2011). Excessive glucocorticoid synthesis in Cushing’s syndrome has now been reported to hasten osteoporosis (Kawamata et al., 2011). Furthermore, several inflammatory disorders, including rheumatoid arthritis, may necessitate long-term glucocorticoid medication, which has now been linked to secondary osteoporosis. Glucocorticoids, in particular, are thought to be even more prevalent drugs associated to drug-induced osteoporosis (Buckley et al., 2017). Reduced blood supply in radiotherapy and chemotherapeutic therapies focused resistant cancerous cells via modifying the bones microenvironment as well as inhibiting them from establishing a quiescent state. Such results indicate that limiting radiation- and chemotherapy-induced pericyte growth via blood supply manipulation may augment existing anticancer therapeutic strategies for managing or preventing bone metastases (Singh et al., 2019).

Bones have the ability to regenerate as part of the healing mechanism after an accident or trauma, including musculoskeletal growth and ongoing remodeling throughout adulthood. In order to maximize osseous fixing and re-establish skeletal function, bone rehabilitation is composed of a very well sequence of biochemical pathways of bone initiation and conduction, comprising a set of cell types and extracellular and intracellular molecular-signaling pathways, with a distinguishable spatial and temporal sequence (Einhorn, 1998; Cho et al., 2002; Bates et al., 2018). The much more prevalent form of osteogenesis in the clinical context is fracture repair, which mimics the typical embryonic osteogenic cascade, comprising of endochondral and intramembranous bone formation. Almost all of the orthopaedic traumas cure without the development of scar tissue, and bone regenerates like its pre-existing qualities completely recovered, with the freshly formed bones finally unidentifiable from the nearby healthy bone (Ferguson et al., 1999; Dimitriou et al., 2011). Conversely, there are examples where bone regrowth is hindered during bone remodeling, about 13% of tibia fractures being linked with fracture non-union or disorder union. Furthermore, there are other situations in oral and maxillofacial and orthopaedic surgical procedure where substantial quantities of bone healing are needed, including bony restoration of large bone defects caused by tumour resection, trauma, bone deformities, and infection, or situations wherein the regenerative procedure is impaired, like osteoporosis and a vascular necrosis (Audige et al., 2005).

Presently there are a variety of medical procedures in the surgeon’s therapeutic strategies for all of the mentioned scenarios wherein the natural process of bone healing is either damaged or simply ineffective, that could be employed by itself or in conjunction for the augmentation or management of these complicated clinical situations, which can frequently be resistive to therapy, constituting a medical and economical challenge. Distraction osteogenesis and bones transfer are two common techniques used in clinical practice to accelerate or enhance bone healing. A variety of bone-grafting techniques, including allografts, autologous bone grafts, growth factors, and bone-graft replacements are also used (Aronson, 1997; Giannoudis et al., 2005; Giannoudis and Einhorn, 2009).

**TRADITIONAL CHINESE MEDICINES IN OSTEOPOROSIS AND BONE REGENERATION**

Since ancient times, Traditional Chinese medicines (TCM) were used in hospitals and private clinics to cure skeletal disorders, and it is an economical substitute to commercialized pharmaceutical medicines. TCM are used in more than 130 countries across the globe. It is assumed that the application of TCM on damage tissues effect directly on the traumatized organ and trigger improvements and bone healing. Traditional Chinese Medicine’s extensive use for musculoskeletal disorders has endured the test of time in both rural and urban settings. In joint sprains, inflammatory disorders, and even fractured bones, topical applications of natural remedies are useful (Hsiao, 2007; Mukwaya et al., 2014). TCM has already been utilized for the management of musculoskeletal disorders, particularly bone fractures, osteoporosis, and rheumatism with great success (Mukwaya et al., 2014). TCM evolved from mythological therapy into a herbal medicine system. The impacts of several Chinese medicines were examined and vetted over many years of clinical practice. TCM differs greatly from modern medicine in terms of practice and theory (Wong and Rabie, 2006). TCM was added in the 11th edition of the International Statistical Classification of Diseases and Related Health Problems by the World Health Organization (WHO) in 2018 (Organization, 2004).

TCM is a discipline of conventional remedy that encompasses herbal medication, massage (tui na), acupuncture, food, and exercise (qigong) therapy. All these approaches are equally practiced, in this review, however we will be more focusing on herbal medication component of the Traditional Chinese Medicine. It is based on more than 2,500 years of Chinese healthcare profession (Sheng et al., 2012). The zhàng-fú theory is among the fundamental concepts of TCM. The terminology zhàng focuses on five key components, which include the liver, heart, lung, kidney and spleen, which include the stomach, gallbladder, small intestine, urine bladder, large intestine, and Sánjīào. The kidneys are some of them, and it is thought to be associated to skeletons. In contrast to the Modern health conception of kidneys, the TCM idea of kidneys seems more like a method of characterizing a group of interconnected components than a physiological organ. The kidney’s primary duties are to build bones, control human growth and development, and generate marrow to fill the brain. Numerous kidney-nourishing herbal medications can restore bones, as per the Chinese medicine kidney theory, and are thus prescribed to cure bone-related disorders including osteoporosis. One of these medicines’ mode of action might increase osteoblastogenesis (Liu, 2018; Matuk, 2006). According to published research findings, such traditional Chinese medicines for the therapy of
osteoporosis seem to have both anabolic and antica
tabolic impacts besides boosting osteogenesis and
minimising unbalance osteoclast activity, resulting in
enhanced bone mineral density and biomechanical
properties, as well as diminished bone microstruc
tural degeneration (Figure 1) (He et al., 2017; Suvarna et al., 2018).

Bone regeneration is a sophisticated biochemical
procedure that starts with localized hemorrhage
and inflammation, and then proceeds to the produc
tion of cartilage, soft extracellular matrix tissue,
and fresh bone via the complex actions of mesenchymal progenitor cells. TCM emphasizes on the
total influence of the patient’s body on the bone les
sions in healing musculoskeletal disorders, rather
than just the local therapy as is usual in western
treatment. Therefore, TCM uses both interior therapies in
conjunction to external therapy. TCM considers 3 phases
when it comes to bone deformities: 1) during first phase, there
is harm to the blood vessels due to stagnation of “qi” and blood,
and also obstructed meninges, which together leads to pain; 2) in
the second phase, the inflammation eventually subsides and the
pain is significantly reduced, but the bruises remain, and
connective tissues are not repaired; 3) in the third phase, the
overall bone damage has now been healed, but remedy to pacify
and improve bone regeneration, and improve the internal
environment is yet required (Tang et al., 2021; Zhang et al.,
2021). Icariin (ICA) being a traditional Chinese medicine which
was found to repair the vascular system and successfully
modulate intracellular senescence in bones. Furthermore, it is
unknown if ICA can impact endothelial cells’ angiogenic capacity
through changing apoptosis (Li et al., 2022). Traditional Chinese
medicines having bone regeneration and antiosteoporosis activity
are summarized in Table 1.

Herba Epimedi

The dried aerial component of Epimedium species like
Epimedium sagittatum (Yin Yang Huo) is known as Herba
Epimedi (HE). HE is among the best commonly
recommended herbs in Chinese osteoporosis formulations
(Qin et al., 2005). The plant is harvested, stripped of stiff
stems and unwanted particles, and shade or Sun drying is
done in the autumn and summer. Sichuan, Shaanxi, Guangxi,
Liaoning, and Hubei states yield the majority of it. Flavonoids,
phenolic glycosides, ligans, penethylol glycosides, ionones and
sesquiterpenes have all been extracted from Epimedium species.

In an aging or ovariecto-mized (OVX) rat model, HE as a solo
herb or even as a herb combination could prevent bone
resorption (Zhu, 1998; Wong and Rabie, 2006). According to
Gao, in vitro production of the chick embryo femur was
stimulated by Epimedium in injectable formulation (Gao,
1985). HE extract has been shown in clinical trials to inhibit
bone resorption and enhance E2 and osteocalcin concentrations.
In OVX rats, the total flavonoid fraction of HEP started to
improve BMD, increased E2 levels, and lowered systemic IL-6
levels (Jiang et al., 2002). Icariin, a flavonoid biomarker in HE, is
thought to be the main bioactive element responsible for its bone-
regeneration properties (Wong and Zhang, 2013). In an
experiment conducted, OVX C57BL/6 test mice were injected
icariin at a dose of 0.3 mg/g day for 6 weeks to determine the in
vivo bones protecting properties of the compound. Icariin was
reported to prevent the degradation of bone density and integrity
in the femur bone (Mok et al., 2010).

Bone and bone marrow vascular are essential for supply of
nutrients, oxygen, and secrete angiocrine factors essential for
maintenance, survival, and self-renewal of progenitor and stem
### TABLE 1 | Summary and mechanism of Traditional Chinese medicines (TCM) used for bone regeneration and antiosteoporosis.

| TCM | Extract/compounds | Study type | Effect on bones | References |
|-----|-------------------|------------|----------------|------------|
| Psoralea corylifolia | Extract | In vivo | Increase bone calcification and hyperosteoideosis | Miura et al. (1996) |
| Gynochthodes officinalis | Extract | In vivo, in vitro | [Bone Mineral Density, [Bone Mineral Content, [Bone P, Ca+] Increases tibia | Seo et al., 2005; Li et al., 2009; Li et al., 2013 |
| Eucamnia ulmoides | Cortex extract | In vivo, in vitro | [Bone Mineral Density, [Bone microarchitecture | Wong et al., 2007; Cao et al., 2008 |
| Curculigo orchioides | Extract | In vivo, in vitro | [Bone Mineral Density, [Bone microarchitecture | Li et al., 2013 |
| Cuscuta chinensis | Kaempferol | In vivo | [Bone Mineral Density, [Bone microarchitecture and biomechanical parameters | Chang et al., 2006; Liang et al., 2012 |
| Epimedium brevicornum | Icarin, flavonoids | In vivo, in vitro | [Bone Mineral Density, Increases serum ALP, microarchitecture and biomechanical parameters | Vickers, 2017 |
| Herbep erimedi | Icarin, icarin | In vivo | Improve osteoblast differentiation and proliferation | Wang et al., 2017b; Tang et al., 2018 |
| Fructus ligustri lucidum | Ligustrum flavonoids, salicinolid | In vivo | Activate osteoblast proliferation and bone development by BMP2/Smad activation | Chen et al., 2011 |
| Rhizoma drynariae | Total flavonoids | In vivo | Augment osteoblast function through BMP2/Smad cascade | Huh et al., 2006 |
| Puerariae radix | Puerariae radixextract | In vivo | Increases osteoblast formation | Lee et al., 2009; Liu et al., 2014a |
| Euoptae herba | Wedelolactone | In vivo | Stimulate osteoblast differentiation and bone formation | Yang et al., 2016 |
| Astragalus membranaceus | Extract | In vivo | Stimulate fresh bone development on periodontal defects | Kihara et al., 2011 |
| Acer nikoense Maxim | Acerogenin A | In vitro | [BMP-2, BMP-7, BMP-4], Stimulate osteoblast | Lee et al., 2011a |
| Caragana sinica Rhed | Kobophenol A | In vitro | [NO-induced necrosis], regulate NF-kB, AP-1 and JNK signaling pathways, Augment osteoblast function | Choi, 2011 |
| Picrorhiza kuroo Royle ex Benth | Apocynin | In vitro | [IL-6, ROS and TNF-α], Stimulate osteoblast | Choi, 2011 |
| Magnolia oficinalis | Honokiol | In vitro | [Bone Mineral Density | Xiao et al., 2014 |
| Sambucus williamsii Hance | Vanillic acid | In vitro | [MAPK (MEK/ERK) mediated signaling pathway, | Xu et al., 2014 |
| Salvia miltiorrhiza | Salvinolic acid B | In vitro | [ERK signaling pathway, | Huang et al., 2015 |
| Radix Ophiopogon japonicas | Ophiopogonin D | In vitro | [ROS; the FoxO3α-β-catenin signaling pathway, | Li et al., 2011 |
| Drynaria rhizome | Neocerinotinic, Naringin | In vitro | [Runx2, ALP] | Li et al., 2011 |
| Poncirus trifoliata | Poncin | In vitro | [IL-6, TNF-α], Increase bone calcification and hyperosteoideosis | Yoon et al., 2011 |
| Fruits and vegetables | Quercetin | In vitro | [MAPK- and ERK-mediated pathway, | Lee et al., 2011b |
| Ginseng | Ginsenoside-Rb2 | In vitro | [ALP, Oinx, Runx2] Increase bone calcification and hyperosteoideosis | Srivastava et al., 2013 |
| Saussurea lappa | Costunolide | In vitro | [P38, JNK, PKC, ERK, p38 | Li et al., 2014 |
| The genus Rhamnus | Emodin | In vitro | [BMP-2, P38, Akt and MAPK] pathways | Lee et al., 2008 |
| Cnidium monnieri | Imperatorin | In vitro | [Bone Mineral Density, [Bone microarchitecture | Tang et al., 2008 |
| Sophora japonica | Genistein | In vitro | Provokes ERa regulation via MAPK/ERK-βB/AP-1 pathway | Liao et al., 2014 |
| Rhodiola rosea | Salidroside | In vitro | [BMP-2, BMP-7, phosphorylation of ERK1/2 and SMAD 1/5/8] | Chen et al., 2013 |
| Herba siegesbeckia | Kireno | In vitro | [BMP-2, β-catenin], BMP and Wnt/β-catenin pathways | Kim et al., 2014 |
| Bu-Shen-Tong-Luo Decoction | Combination of three ancient Chinese formulae | In vivo | [Bone resorption and angiogenesis | Yuan et al., 2018 |
cells. Vasculature produces nurturing slots for blood-forming stem cells and bones in the skeletal system. Hematopoiesis is regulated by intact blood vessels and also aid in the formation of bones during repair, development, and re-generation. Malfunctioning of vasculature induces bone diseases, skeletal aging, and blood disorders (Chen et al., 2020). Physical activity can improve blood supply and vascularization to an organ, however, the curative/preventive potentials of physical activity on bone repair due to contribution of vascularization due to such activities have not been investigated specifically (Wazzani et al., 2021). The two major components Icaritin and Icariin of Epimedium sagittatum (Yin Yang Huo) also known as Herba Epimedii (HE) have been shown to have prominent effects in vascularization and bone formation. Icaritin reduced the incidence of steroid-associated osteonecrosis and inhibited intravascular thrombosis and extravascular lipid-deposition upon oral administration to rabbits (Zhang et al., 2009a). Similarly, an icariin/tricalcium phosphate porous scaffold enhanced new vascular and bone formation in a rabbit model of femoral head osteonecrosis after 12 weeks of treatment (Xie et al., 2015).

By methodologies of cell culture in vitro and detection of 3H-TdR integrating DNA of bone marrow cells, Liu et al. investigated the impact of Epimedium sagittatum polysaccharides on DNA replication of bone marrow cells of “yang deficiency” animal model produced by hydroxyurea. The findings demonstrated that following 100 μg dose of Epimedium sagittatum polysaccharides were applied, cell multiplication improved by 72% and DNA replication enhanced by 68 percent (Liu et al., 1991). Yu et al. investigated the effects of the Chinese herb Guizhou epimedium on osteoporosis and osteoclastic bone resorption. In order to evaluate the activity of the Chinese herb in vitro, osteoclasts were extracted and cultivated. The in vivo activity of this herb had also been studied in rats that had osteoporosis caused by ovariectomy, and the findings were correlated to the impact of estradiol in the similar group of rats. The epimedium was found to decrease osteoclastic degradation of bones in an in vitro research. Apparently the estradiol and epimedium enhanced new vascular and bone formation in a rabbit model of femoral head osteonecrosis after 12 weeks of treatment (Xie et al., 2015).  

**Curculigo orchioides Gaertn**

Curculigo plants have been reported in over 20 different species around the globe. They are indigenous to South America, Africa, Asia and Oceania’s tropical and subtropical climates. Curculigo orchioides is a kind of curculigo. In Chinese medicine, Curculigo orchioides Gaertn (COG, “Xian Mao”), it was applied topically for the management of knee and spine joints arthritis, leg fatigue and diarrhoea. COG seems to have antitumor effects and antioxidant, and could be employed as an antisteoporotic herbal agent, according to latest research (Ramchandani et al., 2014; Vickers, 2017; Hejazi et al., 2018; Cui et al., 2019). COG has been studied in vivo for its antisteoporotic activities in TCM for the management of postmenopausal women with osteoporosis. COG reduced trabecular bone degradation in ovarietomized rats’ tibias by reducing osteoclast activity and boosting serum calcium, phosphorus and OPF levels while having no effect on body or uterus size. After COG dosing, serum concentrations of bones degradation associated makers like corticosterone, TRACP, DPD/Cr, and ACTH were reduced (Cao et al., 2008). COG might even stimulate bone regeneration after healing process, according to Wong et al. COG’s principal biologically active component, curculigoside (CGG; phenolic glycoside), is reported to have antisteoclast and osteogenic properties (Wong et al., 2007; Liu et al., 2014b).

Curculigoside upregulated the osteogenic action in human amniotic fluid derived stem cells in a dose-dependent way, according to a latest in vitro analysis, which revealed that CCG up-regulated osteogenic action in a dose-dependent way, such as upregulation of Collagen I and osteopontin,
increased the ALP action, and calcium accumulation. The observation that Cyclin-D1 and β-catenin are both upregulated at the same time suggests that such actions are regulated through the β-catenin/Wnt signaling cascade (Liu et al., 2014b). By modulating osteogenic growth, differentiation, and proinflammatory cytokine concentrations, CCG has indeed been demonstrated to prevent rat calvarial osteoblasts from dexamethasone (DXM)-induced toxicity. The consequences of DXM on the concentrations of osteoblast development biomarkers such as OPG, ALP and β-catenin were reversed, suggesting that CCG could be a good candidate for the management of postmenopausal osteoporosis (Zhu et al., 2015). Phytochemicals extracted from COG have been demonstrated to exhibit antiosteoporotic effects in vitro and in rat calvarial investigations, such as the encouragement of osteoblast differentiation and proliferation, enhanced bone forming activities, and suppression of osteoclastogenesis (Jiao et al., 2009; Wang et al., 2017c). In summary, C. archioides' induction of osteogenesis may be a good impact resulting in reduction of osteoporosis, and the medicine’s suppression of ROS is a valuable quality. Furthermore, several COG-derived compounds have been shown to inhibit osteoclastic demineralization. More exploration is needed to establish the therapeutic constituents of COG, molecular pathways, and signalling routes as well as the biochemical basis of osteoporosis.

**Fructus Ligustri Lucidi**

Fructus Ligustri Lucidi (FL) is most often used to purify the kidneys and augment the bones as a singular herb. In ovariectomized rats which were fed whether with a regular 0.6% Ca dietor a reduced 0.1% Ca diet, orally, FL extract enhanced bone density and bone's mechanical integrity at the diaphysis of femurs, tibia and lumbar vertebrae. Additionally, FL modulates calcium equilibrium in older women by modifying the parathormone's vitamin-D axis and increasing absorption of calcium in vivo, implying that FL might be an appropriate therapy for restoring calcium and vitamin-D equilibrium (Haung and Yang, 2003; Zhang et al., 2008a; Zhang et al., 2008b). Even though oleanolic acid, the significant bioactive compound in FL, had enhanced the osteoblastic delineation of osseous mesenchymal stem cells and osteoprotective activity in ovariectomy-induced osteoporotic rats in vitro, more research is needed to determine whether this chemical contributes to the regulatory oversight of FL on calcium equilibrium (Haung and Yang, 2003).

**Er-Xian Decoction**

Er-Xian decoction (EX) is a multi-herb composition consisting of six different herbs: Cortex phellodendri, Radix morindae officinalis, H. epimedi, Rhizome curculiginis, Radix angelicae sinensis and Rhizome anemarrhenae. It has proven effective in reducing osteoporosis, perimenopausal syndrome, and ageing problems in older patients. It is therapeutically useful in alleviating menopausal symptoms by boosting the level of circulating estradiol. EX alleviated the menopausal symptoms by increasing antioxidant and endocrine activity, through the stimulation of catalase (CAT) and aromatase detoxification channels (Liu et al., 2005; Sze et al., 2009). EX has been proven to have anti-osteoporotic actions comparable to estrogens and has attributed enormously to the prophylaxis or therapy of bone loss caused by ovariectomy in rats. It has beneficial effects on bone while having just minimal impact on the uterus, demonstrating that EX is acceptable to be used for bone health management (Nian et al., 2006).

**Eucommia Ulmoides Oliv**

Eucommia Ulmoides Oliv (EO) is the extract of leaf and cortex that has reported to inhibit osteolysis and bones density depletion, as well as stimulate osteogenesis. Ha and his co-researchers investigated the phytochemicals in a portion of extract of Eucommia cortex and found that these constituents play active role in every sequence of the pathways for initiating osteoblast to expedite osteogenesis and impeding osteoclast action to block osteolysis by evaluating on osteoporosis the clinical efficiency of these crude extract, like methanol, ethyl acetate, chloroform, aqueous, and butanol fractions. The oral administration of EO over a 4-month time frame in adult OVX rats was found to prohibit the degradation of trabecular micro-architecture and loss of estrogen deficiency-induced osseous micronutrients, thus sustaining physiological fluency of the bone. Moreover, EO juice was reported to activate the secretion of GH, controlling bone growth, development and bone formation, implying that EO could be a promising candidate for the treatment of osteoporosis (Ha et al., 2003; Zhang et al., 2009b).

**Fructus Psoraleae (Bu Gu Zhi)**

The dehydrated mature fruits of the perennial herb *Psoralea corylifolia* L. are known as Bu Gu Zhi. It belongs to family Leguminosae. The plant is harvested and processed in the autumn. After that, the fruit is scraped clean and free of extraneous debris. Anhui, Shanxi, Henan, and Sichuan states yield the majority of the plant. Healthy rats were given the acetone seed extract (the n-hexane ethyl acetate elution) of P. corylifolia, which resulted in a considerable increase in bones mineralization and serum inorganic phosphorus. Bone regeneration and serum levels of phosphorus were elevated in rachitic rats (already nourished with vitamin D free diet) when n-hexane elution were orally administered. In rachitic rats, administration of n-hexane elution showed a significant reduction in osteoid quantity and an enhancement in hyperosteoides. These findings indicate that n-hexane elution could be effective treatments for osteomalacia, osteoporosis, broken bone, and other skeletal disorders (Ma et al., 1996; Miura et al., 1996). *Psoralea corylifolia* L. fruit preparations stimulated osteoblastic development in an in vitro grown UMR106 cell line, according to Wang et al. By using activity-guided fractionation, the flavonoids bavachin and corylin have been recovered and defined as bioactive components. These findings indicate that *Psoralea corylifolia* L. fruit preparations, as well as bavachin and corylin, may induce bone production or have anti-osteoporosis effect (Wang et al., 2001).
Epimedium davidii Franch (Icarin, and Icaritin)
Epimedium davidii Franch (EDF) was used to cure osteoporosis for decades, attributed to its ability to "develop" bones. Icarin is the major bioactive flavonoid glucoside extracted from EDF and it is linked to the herb’s pharmacological activities. Nevertheless, in current years, its bone-strengthening properties have gotten a lot of publicity. Icarin boosts antiosteoporotic action by promoting osteogenic development and calcification, decreasing adipogenesis, blocking osteoclast formation, and causing osteoclast death, all of which reduce osteoclast activity and bone resorption (Li et al., 2014b; Xu et al., 2016). Icarin may boost Nitric oxide (NO) production by increasing osteoblast development and matrix calcification. Subsequent research revealed that icariin therapy increased the expression of SMAD4, BMP-2, OPG, and Cbfa1/Runx2 genes while decreasing the expression of RANKL. This action might lead to its effects on osteoblast multiplication and development, which results in osteogenesis (Li et al., 2014b). Liang’s findings also showed that icariin might enhance osteogenesis in hFOB 1.19 cells via activating the BMP-2/Smad4 signaling cascade (Figure 2) (Liang et al., 2012). Icaritin, an icariin endogenous product, has a comparable performance to icariin. In vitro and in an OVX rat, oral administration of icariin suppressed osteoclastogenesis by downregulating TRAF6 and inhibiting the NF-kB, MAPK/AP-1, and reactive oxygen species signalling cascades in a synchronized approach to diminish NFATc1 expression and activities (Tan et al., 2017). According to Wu and Sheng, icaritin increased the protein content of osteocalcin BMPs, and Runx2 in human adipose tissue-derived stem cells and derived mesenchymal stem cells while impeding adipogenesis in marrow mesenchymal stem cells by suppressing peroxisome proliferator-activated receptor gamma and glycogen synthase kinase-3 (Sheng et al., 2013).

TCM enhanced the Sema7A and sema3A-mediated signaling cascade, which is stimulated downstream of β-catenin nuclear translocation, and boosted the stimulation of the Smad1/5/8 and BMP2 pathway, leading to an increase in osteoblastogenesis.

Eclipta prostrata (Mo-Han-Lian)
The aerial components of Eclipta prostrata (Asteraceae), often termed as “Mo-Han-Lian,” contain antiosteoporotic potential. Ecliptae herba produces the chemical wedelolactone. Though this Ecliptae herba ethyl acetate extract and wedelolactone had no effect on BMSC growth, the extract and wedelolactone did improve BMSC development into osteoblasts. The extract was given orally as well as applied topically on the fractured site. When BMSCs are incubated with wedelolactone, the production of ALP, a diagnostic enzyme for mature osteoblasts, increases in a dose-dependent way. In addition, wedelolactone caused an elevation in bones calcification. Wedelolactone suppressed GSK3 function and increased GSK3 phosphorylation at the molecular scale, which therefore boosted nuclear translocation of β-catenin. The expression of genes associated to osteoblastogenesis, such as osteocalcin, osteorix, and runx2, was elevated. Wedelolactone treatment to ovariectomized rats reduced ovariectomy induced bone resorption by increasing osteoblast activation and stimulating osteogenesis (Zhang et al., 2008c; Zhang et al., 2013; Liu et al., 2016).

Salvia miltiorrhiza
Researchers investigated the anti-osteoporotic potential of 99 distinct Chinese herbal remedies in 108 randomized studies involving 10,655 Chinese subjects. Salvia miltiorrhiza was present in 16 of the investigations. TCM therapy was contrasted to Western medication (like vitamin D2, caltrate,
alendronate, and calcitonine) in 61 studies, including 23 natural treatment investigations showing a considerable benefit in boosting bone mineral density (BMD). In 48 researches the impact of combining Western medicines with Chinese herbal medicine, 26 found that the combined treatment had a greater effect on BMD versus Conventional medicine solo. The subsequent studies had equivalent results or were significantly lesser effective. Standard medicines such as denosumab, bisphosphonates, and selective oestrogen receptor stimulators have often been or not included in the controlled research utilizing Western medicine. Calcitriol caltrate, calcitonin, and vitamin D were the most often utilized Western medicines in the normal control in investigations including Salvia miltiorrhiza, whereas a bisphosphonate (alendronate) was given once only (Liu et al., 2014c).

**NETWORK PHARMACOLOGY APPROACH FOR ACTIVE INGREDIENT IDENTIFICATION**

Traditional Chinese medicine usually contain many components and the main issue of application of such combinations is that they contain the effective therapeutic components that have been identified or not yet and involve various unknown elements, some of which may have underlying toxicities. Therefore, it is extremely important to extract only these therapeutic components and avoid risks posed by the administration of raw herbal medicine. Therefore, there is a need to propose potent approaches to identify those therapeutic elements and extract them. In recent years, computer technology along with endless innovations and development in systems biology, a network pharmacology (NP) approach has been adopted which has shown applicational value in many fields, including drug target identification, discovery of active ingredients, investigation of mechanism of action, and safety evaluations (Ye et al., 2014). It was proposed for the first time in 2007 by Hopkins and is now believed as a promising approach which combine systems medicine with information science (Hopkins, 2007). It give an efficient approach for evaluation of the synergy of components of TCM and their mechanisms (Zhang et al., 2020) and has been widely used for the overall molecular mechanism of TCM preparations or multi-drug combinations (Ye et al., 2016). Bioinformatics tools are used to obtain differentially expressed genes (DEGs) as disease targets (e.g., Osteoporosis), and then effective components and pharmacological mechanism of TCM in the treatment of the disease are analyzed by network pharmacology. Various studies have reported this approach for the investigation of mechanism of TCM in treatment of Osteoporosis. For example, Li et al. used this approach for investigation of the mechanism of Xianlinggubao capsule in the treatment of osteoporosis (Li et al., 2021). They found that the active components (luteolin, quercetin, apigenin and ursolic acid) of Xianlinggubao capsule could be responsible for the mineralization of MC3T3-E1 cells. Similarly, Yang et al., used Network pharmacology approach combined with molecular docking to investigate the Potential Mechanism of Jintiange Capsule for the treatment of Osteoporosis and found that calcium phosphate (the main active ingredient), may interact with CALR and CALM1 targets and regulate multiple signaling pathways to treat osteoporosis (Yang et al., 2021). Gan et al. used NP approach for investigation of the mechanism of Rhizoma drynariae (TCM) against Osteoporosis and found 16 active ingredients that directly or indirectly target multiple signaling pathways and affect the differentiation and proliferation of multiple types of cells (Gan et al., 2019). There are many other examples where this approach has been used for identification of major components responsible for the treatment of osteoporosis and their possible mechanism has been provided. Yet, it is extremely important to extract only these therapeutic components and avoid risks posed by the administration of raw herbal medicine.

**FUTURE PROSPECTS**

Accidental injuries and malignancies create bone abnormalities, which are widespread in clinical practice. High costs and long treatment cycles, uncontrolled curative impact, and problems such as infection, nonunion and malunion, of bones define existing bones defect therapies. These concerns not only have a negative impact on patients’ physiological and emotional health, but they also pose a difficulty for orthopaedic surgeons. The natural Chinese medications discussed in this article are both traditional and bone-specific. Therapeutic skills, as we all knew, are quite significant in Chinese medicine. As per the rich practises and expertise in the clinics, as well as Chinese medicine concepts, Chinese medications were grouped into several groups with specific functions. Many of them have been traditional and bone-specific medications used to manage bone injuries and bone—related illnesses because they improved bone production. In traditional Chinese medicine, the majority of them have the impacts and activities of tonifying the “Yang,” which improves bone formation and metabolism. In Chinese medicine, “yang-tonifying” medications are common and traditional type of natural remedies used to prevent osteoporosis (Ju et al., 2014; Li et al., 2015). Several clinical trials have demonstrated the antiosteoporosis actions of well substances, such as Epimedium derived phytoestrogen flavonoids, which were employed in a clinical study to cure and suppress osteoporosis and bone resorption in older women (Zhang et al., 2007; Zhu et al., 2012; Wang et al., 2013; Shi et al., 2017; Liang et al., 2020). TCM formulations offer less adverse effects, have become less expensive, and may be used for a prolonged time. TCM formulations not only can restore bones microarchitecture, enhance bone mass, and promote bone physiological qualities, but could also lessen or eradicate spinal debilitation, backache, as well as other complaints, according to a large body of clinical settings and animal experimentation (Zhu et al., 2012).

The modes of action of natural Chinese medicines that are efficacious in curing osteoporosis has not been thoroughly examined, emphasising the urgency for more research. To fully evaluate substances for pharmaceutical use, more studies are
needed to identify and describe active antosteoporotic molecules from traditional and bone-specific medications, as well as their safety, effectiveness, and probable interactions with other treatments. To establish their promising implications for the therapy of osteoporosis, as an efficient, potential substitute to principal treatment interventions, or in conjunction with existing main treatment modalities, research works to establish the special and focused molecular and cellular mechanisms of Traditional Chinese medicine substances are required.

CONCLUSION

Countless trials have been performed to examine the pathophysiology of osteoporosis. Immunomodulatory modulation of osteoporosis is a new scientific focus that presents a novel method of osteoporosis etiology. The therapeutic potential of Traditional Chinese herbs in the management of osteoporosis has been demonstrated. Further investigation is necessary, but a growing number of researchers have shown that these herbs have an essential part in the rehabilitation of osteoporosis by modulating the immune system. Traditional Chinese medicine’s mode of action is notable for being multiroute and multitargeted, rather than a singular mechanism. Traditional Chinese medicine has therapeutic value for the management of osteoporosis, according to current in vitro and in vivo findings. To fully understand the therapeutic potential of Chinese medicines, more investigation is required to confirm their safety, potency, and accuracy. Further high excellence clinical trials using these traditional remedies are required to offer additional evidence for the candidate’s antosteoporotic usage to be efficacious and non-toxic.

AUTHOR CONTRIBUTIONS

ZP: Manuscript writing. RX: Reviewing and finalizing the manuscript. QY: Data collection.

REFERENCES

Anderson, G., Sun, J., and Theriault, B. (2002). The Effect of Gu-Sui-Bu (Drynaria Fortunei) on Bone Cell Activity: A Preliminary Study. J. bone mineral Res. 17, S454.

Aronson, J. (1997). Current Concepts Review - Limb-Lengthening, Skeletal Reconstruction, and Bone Transport with the Ilizarov Method. J. Bone & J. Surg. 79 (8), 1243–1258. doi:10.2106/00004623-199708000-00019

Audigé, L., Griffon, D., Bhandari, M., Kellam, J., and Rüedi, T. P. (2005). Path Analysis of Factors for Delayed Healing and Nonunion in 416 Operatively Treated Tibial Shaft Fractures. Clin. Orthop. Relat. Research® 438, 221–232. doi:10.1097/0b000001363866906.74

Bartl, R., and Frisch, B. (2004). “Definition of Osteoporosis,” in Osteoporosis (Springer), 24–32. doi:10.1007/978-3-662-09163-0_3

Bates, P., Yeo, A., and Ramachandran, M. (2018). Bone Injury, Healing and Grafting. Basic Orthop. Sci. Vol. 205, 215–222. doi:10.1210/bos115117294-14

Bone, H., Mcclung, M. R., Ince, A., and Verbruggen, N. (2007). A Randomized Double-Blind, Placebo-Controlled Study of a Cathepsin K Inhibitor in the Treatment of Postmenopausal Women with Low BMD: One Year Results. J. Bone Min. Res. 22 (Suppl. 1), S37. doi:10.1016/j.jbmr.2007.12.136

Buckley, L., Guyatt, G., Fink, H. A., Cannon, M., Grossman, J., Hansen, K. E., et al. (2017). 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis & Rheumatology 69 (8), 1521–1537. doi:10.1002/art.40137

Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., and Tosteson, A. (2007). Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005-2025. J. Bone Min. Res. 22 (3), 465–475. doi:10.1359/jbmr.061113

Cao, D. P., Zheng, Y. N., Qin, L. P., Han, T., Zhang, H., Rahman, K., et al. (2008). Curculigo Orchioides, a Traditional Chinese Medicinal Plant, Prevents Bone Loss in Ovariectomized Rats. Maturitas 59 (4), 373–380. doi:10.1016/j.maturitas.2008.03.010

Chen, J.-J., Zhang, N.-F., Mao, G.-X., He, X.-B., Zhan, Y.-C., Deng, H.-B., et al. (2013). Salidroside Stimulates Osteoblast Differentiation through BMP Signaling Pathway. Food Chem. Toxicol. 62, 499–505. doi:10.1016/j.fct.2013.09.019

Chen, J., Hendriks, M., Chatzis, A., Ramasamy, S. K., and Kusumab, A. P. (2020). Bone Vasculature and Bone Marrow Vascular Niches in Health and Disease. J. Bone Min. Res. 35 (11), 2103–2120. doi:10.1002/jbmr.4171

Chen, L.-I., Lei, L.-h., Ding, P.-h., Tang, Q., and Wu, Y.-m. (2011). Osteogenic Effect of Drynariae Rhizoma Extracts and Naringin on MC3T3-E1 Cells and an Induced Rat Alveolar Bone Resorption Model. Archives Oral Biol. 56 (12), 1655–1662. doi:10.1016/j.archoralbio.2011.06.008

Cho, T.-J., Gerstenfeld, L. C., and Einhorn, T. A. (2002). Differential Temporal Expression of Members of the Transforming Growth Factor β Superfamily during Murine Fracture Healing. J. Bone Min. Res. 17 (3), 513–520. doi:10.1359/jbmr.2002.17.3.513

Choi, E. M. (2011). Honokiol Isolated from Magnolia Officinalis Stimulates Osteoblast Function and Inhibits the Release of Bone-Resorbing Mediators. Int. Immunopharmacol. 11 (10), 1541–1545. doi:10.1016/j.intimp.2011.05.011

Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., et al. (2014). Clinician’s guide to prevention and treatment of osteoporosis. Osteop. Int. 25 (10), 2359–2381. doi:10.1007/s00198-014-2794-2

Cui, X., Shang, S., Lv, X., Zhao, J., Qi, Y., and Liu, Z. (2019). Perspectives of Small Molecule Inhibitors of Activin Receptor-like K-inase in A-niti-tumor T-treatment and S-tem C-ell D-ifferentiation (Review). Mol. Med. Rep. 19 (6), 5053–5062. doi:10.3892/mmr.2019.10209

Dai, K.-R., Zhang, P., Yan, S. G., Yan, W. Q., Zhang, C., Chen, D. Q., et al. (2009). Effects of Naringin on the Proliferation and Osteogenic Differentiation of Human Bone Mesenchymal Stem Cell. Eur. J. Pharmacol. 607 (1-3), 1–5. doi:10.1016/j.ejphar.2009.01.035

Dimitriou, R., Jones, E., McGonagle, D., and Giannoudis, P. V. (2011). Bone Regeneration: Current Concepts and Future Directions. BMC Med. 9 (1), 66–10. doi:10.1186/1741-7015-9-66

Dinger, J., Bardenheuer, K., and Heinemann, K. (2016). Drosopine Plus Estradiol and the Risk of Serious Cardiovascular Events in Postmenopausal Women. Climacteric 19 (4), 349–356. doi:10.1080/13697137.2016.1183642

Einhorn, T. A. (1998). The Cell and Molecular Biology of Fracture Healing. Clin. Orthop. Relat. Res. 355S, S7–S21. doi:10.2106/00003086-199810001-00003

Ferguson, C., Alpern, E., Miclau, T., and Helms, J. A. (1999). Does Adult Fracture Repair Recapitulate Embryonic Skeletal Formation? J. Bone Min. Res. 14 (1-2), 57–66. doi:10.1359/jbmr.1999.14.1-2.57

Gao, D., Xu, X., Chen, D., Feng, P., and Xu, Z. (2019). Network Pharmacology-Based Pharmacological Mechanism of the Chinese Medicine Rhizoma Drynariae against Osteoporosis. Med. Sci. Monit. 25, 5700–5716. doi:10.12659/msm.915170

Gao, Z. F. (1985). Stimulant Effect of Epimedium in an Injection Form on the Growth of the Chick Embryo Femur In Vitro. Zhong Xi Yi Jie He Za Zhi 5 (3), 17213–133.

Giannoudis, P. V., Dinopoulos, H., and Tsiridis, E. (2005). Bone Substitutes: An Update. Injury. 36 (3), S20–S27. doi:10.1016/j.injury.2005.07.029

Giannoudis, P. V., and Einhorn, T. A. (2009). Bone Morphogenetic Proteins in Musculoskeletal Medicine. Injury 40, S1–S3. doi:10.1016/s0020-1383(09)00642-1

Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 3 May 2022 | Volume 10 | Article 911326

Peng et al.
